

18 November 2024

**ValiRx PLC**  
**("ValiRx" or the "Company")**

**First Sale of New Product Line**

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update from its wholly owned subsidiary Inaphaea Biolabs Limited ("Inaphaea").

Inaphaea is delighted to confirm customer shipment of its first batch of Patient Derived Cells ("PDCs"). The cells are provided as part of Inaphaea's new range of Assay Ready Reagents ("ARR"). The ARR range can be used directly for assays without the need to grow inhouse by the customer. Although the value of the order is not material, it endorses Inaphaea's product offering and a potential revenue source for the Company.

**Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, commented** "ARRs are a great new addition to our range of PDC products and services. They provide convenient access to mixed cell populations from our extensive biobank of over 450 PDCs in a ready to assay format."

**Mark Eccleston, CEO of ValiRx commented** "This first sale of our new product range is a major milestone for our commercialisation efforts."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

\*\*\* ENDS \*\*\*

For more information, please contact:

<b>ValiRx plc</b> Dr Mark Eccleston, CEO	<b>Tel: +44 (0) 2476 796496</b> <a href="http://www.valirx.com">www.valirx.com</a> <a href="mailto:Mark.Eccleston@valirx.com">Mark.Eccleston@valirx.com</a>
<b>V Formation (Public Relations)</b> Lucy Wharton - Senior PR Executive Sue Carr - Director	<b>+44 (0) 115 787 0206</b> <a href="http://www.vformation.biz">www.vformation.biz</a> lucy@vformation.biz sue@vformation.biz
<b>Cairn Financial Advisers LLP (Nominated Adviser)</b> Liam Murray/ Ludovico Lazzaretti	<b>Tel: +44 (0) 20 7213 0880</b>
<b>Shard Capital Partners LLP (Sole Broker)</b> Damon Heath	<b>Tel: +44 (0) 20 7186 9000</b>

**Notes for Editors**

**About ValiRx**

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: [www.valirx.com](http://www.valirx.com)

**Cautionary statement**

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DISUBVKRSRUAAA